Understanding The Potential of UBE2V1 as A Drug Target (G7335)

Target Name: UBE2V1

NCBI ID: G7335

UBE2V1

Understanding The Potential of UBE2V1 as A Drug Target

UBE2V1 (UBE2V1) is a protein that is expressed in various tissues throughout the body, including the brain, lungs, heart, kidneys, and intestines. It is a member of the UBE2 family of proteins, which are involved in various cellular processes, including cell signaling, DNA replication, and inflammation. UBE2V1 has been identified as a potential drug target due to its unique structure and its involvement in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The UBE2V1 protein is composed of 216 amino acid residues and has a calculated molecular mass of 34.1 kDa. It is a single transmembrane protein that is expressed in the cytoplasm of various cell types. UBE2V1 is involved in several cellular processes, including cell signaling, DNA replication, and inflammation.

One of the unique features of UBE2V1 is its ability to interact with various signaling molecules, including TGF-β1, NF-kappa-B, and PI3K. It has been shown that UBE2V1 can enhance the effects of these signaling molecules, which may have implications for its potential as a drug target.

UBE2V1 has also been shown to be involved in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that UBE2V1 is overexpressed in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that targeting UBE2V1 may be an effective way to treat these diseases.

In addition to its potential as a drug target, UBE2V1 has also been shown to be a useful biomarker for several diseases. For example, it has been used as a biomarker for cancer, including breast, ovarian, and prostate cancer. It has also been used as a biomarker for neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

UBE2V1 is also a good candidate as a potential therapeutic target for treating chronic pain. Several studies have shown that UBE2V1 can inhibit the activity of pain-sensitive neurons, which may have implications for its potential as a pain therapeutic.

In conclusion, UBE2V1 is a protein that is expressed in various tissues throughout the body and has been identified as a potential drug target due to its unique structure and its involvement in several diseases. Further research is needed to fully understand the role of UBE2V1 in cellular processes and to determine its potential as a drug or biomarker.

Protein Name: Ubiquitin Conjugating Enzyme E2 V1

The "UBE2V1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBE2V1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets